Abstract:Abstract Background Preventing congenital cytomegalovirus (cCMV) infection, the most common infectious cause of disability in pediatrics, is a high public health priority. Subunit vaccine studies based on single viral proteins (usually envelope glycoproteins) have yielded disappointing results in clinical trials. In contrast, Disabled infectious single cycle (DISC) recombinant viruses are promising vaccine candidates, offering the potential for a robust immune response against multiple viral immunogens while maintaining an attenuated phenotype. These studies sought to examine the safety and immunogenicity of this strategy in an animal model of vaccine-preventable cCMV infection, the guinea pig cytomegalovirus (GPCMV) model. Design/Methods Vaccine design consisted of introducing a ligand-regulatable FKBP protein destabilization domain, ddFKBP, into an essential viral gene. This domain directs degradation of the tagged protein in cells unless the synthetic compound Shield-1 is present, allowing generation of viral particles capable of single-cycle replication. Two such essential genes, the GPCMV homologs of CMV genes UL51 and UL52 (GP51 and GP52), were targeted for vaccine design. In this study, we sought to test: 1) whether the DISC viruses GP51 and GP52 were attenuated for replication in a guinea pig model; and 2) whether the replication-incompetent viruses retained immunogenicity comparable to a wild-type virus. GPCMV-seronegative guinea pigs were challenged with DISC vaccines GP51 or GP52. Control animals were challenged with wild-type GPCMV (SG24). Animals (3 per group) were infected by subcutaneous injection and boosted at day 21. Blood collected at days 0, 7, 14, 21, 28, 35, 42, and 84 was used for PCR (to gauge attenuation) and serology (to examine immunogenicity). Results Real-time PCR showed a mean viral load of 8.5 x 105 genome copies/mL of blood at day 7 and 9.3 x 104 genome copies/mL at day 14 in guinea pigs that received SG24 compared to 2.9 x 104 and 1.9 x 103 genome copies/mL at days 7 and 14 respectively in recipients of GP51. No viral DNA was detected in recipients of GP52 at either day 7 or 14. These data demonstrate significantly lower viremia in the GP51 and GP52 groups compared to SG24 by two-way ANOVA (p<0.01; Fig. 1A). In spite of marked attenuation, no statistically significant difference in immune response was noted, with equivalent ELISA responses detected upon comparison of animals that received GP51, GP52, or SG24 CMV strains at days 14, 35, or 84 (Fig. 1B). Western blot analysis of sera used to probe fractions containing wild-type viral particles likewise demonstrated induction of a robust antibody response by GP51 and GP52. Conclusion(s) These data suggest that GP51 and GP52 are attenuated for replication but induce an immune response comparable to wild-type infection. Thus, they are promising options in the development of a vaccine to prevent cCMV. Examination of the extent of attenuation against vertical transmission of these DISC viruses, as well as their efficacy as vaccine candidates against cCMV, is warranted. These questions have important implications for potential future human clinical trials. Funding: Supported by 5 T35 AI118620-07, Medical Student Summer Research Program in Infection and Immunity

Perinatal Vaccination by Transamniotic Fetal mRNA Delivery: Immunization Against Human Cytomegalovirus in a Rodent Model

Inclusion of the Guinea Pig Cytomegalovirus Pentameric Complex in a Live Virus Vaccine Aids Efficacy against Congenital Infection but Is Not Essential for Improving Maternal and Neonatal Outcomes

A neutralizing anti-gH/gL monoclonal antibody is protective in the guinea pig model of congenital CMV infection.

Neonatal SARS-CoV-2 mRNA Vaccination Efficacy Is Influenced by Maternal Antibodies

Advancing our understanding of protective maternal immunity as a guide for development of vaccines to reduce congenital cytomegalovirus infections.

In vitro mRNA‐S maternal vaccination induced altered immune regulation at the maternal‐fetal interface

Evaluation of transplacental transfer of mRNA vaccine products and functional antibodies during pregnancy and infancy

Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19–Associated Hospitalization in Infants Aged <6 Months — 17 States, July 2021–January 2022

Cytomegalovirus vaccine: phase II clinical trial results.

Evaluation of mRNA-LNP and adjuvanted protein SARS-CoV-2 vaccines in a maternal antibody mouse model

Pre-existing Maternal IgG Antibodies As a Protective Factor Against Congenital Cytomegalovirus Infection: A Mother-Child Prospective Cohort Study

Immunization with a Multivalent Listeria monocytogenes Vaccine Leads to a Strong Reduction in Vertical Transmission and Cerebral Parasite Burden in Pregnant and Non-Pregnant Mice Infected with Neospora caninum

Efficacy of a respiratory syncytial virus vaccine candidate in a maternal immunization model

Transamniotic Delivery of Surfactant Protein B mRNA in a Healthy Model

Hyperimmune globulin in pregnancy for the prevention of congenital cytomegalovirus disease

Establishing correlates of maternal-fetal cytomegalovirus transmission–one step closer through predictive modeling

Maternal Antibody Improves Active Neonatal Vaccination against RespiratorySyncytial Virus through Immune Complex

Vaccination of pregnant women with respiratory syncytial virus vaccine and protection of their infants

A Novel Strategy to Generate a Recombinant, Live-Virus, Replication Incompetent Congenital Cytomegalovirus Vaccine Candidate

A new era in cytomegalovirus vaccinology: considerations for rational design of next-generation vaccines to prevent congenital cytomegalovirus infection

Preexisting maternal immunity to AAV but not Cas9 impairs in utero gene editing in mice